What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

1 hour ago 2

Jonathan Ponciano, The Motley Fool

Mon, May 18, 2026 astatine 12:44 PM CDT 4 min read

On May 15, 2026, Octagon Capital Advisors disclosed a caller involvement successful Xenon Pharmaceuticals (NASDAQ:XENE), acquiring 490,000 shares successful a transaction estimated astatine $22.58 cardinal based connected quarterly mean pricing.

What happened

According to a filing with the Securities and Exchange Commission connected May 15, 2026, Octagon Capital Advisors initiated a caller presumption successful Xenon Pharmaceuticals, buying 490,000 shares during the archetypal quarter. The estimated transaction worth was $22.58 million, based connected the mean closing terms for the period. The involvement ended the 4th valued astatine $28.49 million, reflecting terms appreciation during the holding period.

What other to cognize

This was a caller presumption for Octagon, present accounting for 3.15% of the fund’s $903.61 cardinal successful reportable U.S. equity assets arsenic of March 31, 2026.
Top holdings aft the filing:
- NASDAQ: DNTH: $163.36 cardinal (18.1% of AUM)
- NASDAQ: COGT: $90.45 cardinal (10.0% of AUM)
- NASDAQ: ABVX: $75.38 cardinal (8.3% of AUM)
- NASDAQ: ALMS: $62.36 cardinal (6.9% of AUM)
- NASDAQ: DFTX: $46.12 cardinal (5.1% of AUM)
As of May 14, 2026, shares of Xenon Pharmaceuticals were priced astatine $56.00, up 85% implicit the past twelvemonth and outperforming the S&P 500 by astir 60 percent points.

Company overview

Metric

Value

Price (as of marketplace adjacent 2026-05-14)	$56.00
Market Capitalization	$5 billion
Net Income (TTM)	($383.17 million)

Company snapshot

Xenon Pharmaceuticals develops clinical-stage therapeutics targeting neurological disorders, including epilepsy and encephalopathy, with a pipeline featuring XEN496, XEN1101, NBI-921352, and XEN007.
The steadfast operates a research-driven concern exemplary focused connected advancing proprietary cause candidates done objective development, leveraging strategical collaborations for prime programs.
It serves patients with neurological disorders and is based successful Canada.

Xenon Pharmaceuticals is simply a clinical-stage biopharmaceutical institution specializing successful the improvement of caller therapies for neurological disorders. With a robust pipeline and strategical partnerships, the institution is positioned to code important unmet aesculapian needs successful epilepsy and related conditions. Xenon's competitory vantage lies successful its expertise successful ion transmission modulation and its quality to advancement aggregate candidates done precocious objective trials.

What this transaction means for investors

Octagon Capital Advisors’ determination is notable due to the fact that the caller presumption instantly became a meaningful portfolio holding, suggesting condemnation that Xenon’s late-stage epilepsy pipeline inactive has country to tally adjacent aft the shares surged 85% implicit the past year.

The biggest catalyst remains azetukalner, Xenon’s pb epilepsy and slump cause candidate. Earlier this year, the institution reported affirmative Phase 3 X-TOLE2 information successful focal onset seizures (FOS), with absorption saying the survey delivered the highest placebo-adjusted efficacy ever observed successful a pivotal FOS study, to its knowledge. Xenon present expects to taxable a New Drug Application to the FDA successful the 3rd 4th of 2026.

Importantly, Xenon has 5 further Phase 3 studies underway crossed epilepsy and slump programs, portion besides advancing symptom cause candidates targeting NaV1.7 and KV7. And financially, Xenon ended March with astir $1.3 cardinal successful currency and marketable securities, which absorption said should money operations into 2029. The communicative present hinges connected conscionable however azetukalner expands crossed aggregate neurological conditions, not conscionable epilepsy.

Read Entire Article